RT Journal Article
SR Electronic
T1 Genomic mapping identifies multiple therapeutic pathways in malignant mesothelioma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.01.23.20018523
DO 10.1101/2020.01.23.20018523
A1 Anca Nastase
A1 Amit Mandal
A1 Shir Kiong Lu
A1 Hima Anbunathan
A1 Deborah Morris-Rosendahl
A1 Yu Zhi Zhang
A1 Xiao-Ming Sun
A1 Spyridon Gennatas
A1 Robert C Rintoul
A1 Matthew Edwards
A1 Alex Bowman
A1 Tatyana Chernova
A1 Tim Benepal
A1 Eric Lim
A1 Anthony Newman Taylor
A1 Andrew G Nicholson
A1 Sanjay Popat
A1 Anne E Willis
A1 Marion MacFarlane
A1 Mark Lathrop
A1 Anne M Bowcock
A1 Miriam F Moffatt
A1 William OCM Cookson
YR 2020
UL http://medrxiv.org/content/early/2020/01/27/2020.01.23.20018523.abstract
AB Malignant pleural mesothelioma (MPM) is an aggressive malignancy associated with asbestos exposure. It shows limited responses to all treatments. Although 20% of tumours may transiently regress after checkpoint immunotherapy1,2, predictors of response are unknown. The molecular landscape is of low complexity but recurrent lesions have not yet defined effective therapeutic targets. In order to comprehensively map genomic alterations, we combined copy-number analysis from SNP arrays with targeted sequencing of tumours from 121 patients. We found previously unrecognised deletions in the tumour suppressor RB1 in 26% of cases. These combined with CDKN2A and TP53 lesions affected the RB tumour suppressor pathway in 65% of tumours. We show here therapeutic avenues downstream of RB1 by finding micromolar half maximal inhibitory concentrations (IC50s) of PLK1, CHEK1 and Aurora Kinase inhibitors in MPM cell lines. Non-overlapping defects in Hippo pathways (RASSF7 amplification, NF2, LATS1 and LATS2 mutations) were present in 48% of tumours, accompanied by micromolar IC50s to the YAP1 inhibitor Verteporfin. Loss of a 240Kb locus containing SUFU was observed in 21% of tumours, accompanied by disordered expression of Hedgehog pathway genes. SUFU depletion was reproducibly associated with reduced transcription of T-cell and macrophage regulators, and increased transcription of the immune checkpoint inhibitor VISTA. In half of all MPM, CDKN2A deletions were accompanied by loss of Interferon Type I genes. The presence of dysregulated Hedgehog immune transcription and loss of Type I Interferons indicate novel approaches to immunotherapy.Competing Interest StatementSP reports honoraria from BMS, Roche, Takea, AstraZeneca, Chugai, Novartis, Pfizer, MSD, EMD Serono, Guardant Health, AbbVie, Boehringer Ingleheim, and Tesaro. All other authors have no competing interests to declare.Funding StatementThis study was financially supported by a Libor Fund grant from the UK Department of Health, and by the Asmarley Foundation. SP acknowledges NHS funding to the Royal Marsden Hospital-Institute of Cancer Research Biomedical Research Centre. We thank Cambridge Biomedical Research Centre and Cambridge Cancer Centre.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequence data is being depositited with the European Genome Archive and will be made freely available following acceptance in a peer-reviewed journal